Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Palforzia

- PMLiVE

J&J signs deal with EU for 200 million COVID-19 vaccine doses

EU member states will have an option to secure 200 million additional doses

- PMLiVE

Nestlé is set to acquire Aimmune in deal worth $2.6bn

Aimmune’s Palforzia therapy is the only FDA-approved peanut allergy drug

EU flag

EU to contribute €400m to WHO’s COVID-19 vaccine facility

Contribution will go towards ensuring equitable access to COVID-19 vaccines

- PMLiVE

EU aims to vaccinate 40% of population in initial COVID-19 blueprint

Target is double the goal set by the World Health Organization

- PMLiVE

COVID-19 vaccine deals with the EU hindered by strict liability rules

Companies would retain liability for unexpected side effects

- PMLiVE

EU concludes discussions with Moderna for COVID-19 vaccine

Biotech company on the verge on finalising supply deal

AstraZeneca AZ

AZ inks deal with EU for 400 million doses of COVID-19 vaccine

Doses will be available to all EU member states at no profit during pandemic

- PMLiVE

FDA knocks back DBV’s peanut allergy therapy once again

Drug loses further ground to Aimmune's Palforzia

- PMLiVE

EU grants approval for Venclyxto/Gazyvaro combo in CLL

Chemotherapy-free option for previously-untreated patients

- PMLiVE

Aimmune’s Palforzia is first peanut allergy drug cleared in US

Shares in the Nasdaq-listed biotech have spiked

- PMLiVE

J&J wins another label expansion for Darzalex in Europe

Multiple myeloma treatment indicated for early use

- PMLiVE

AbbVie’s JAK inhibitor Rinvoq approved in EU for rheumatoid arthritis

Continued expansion for next-generation immunology drug

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links